Navigation Links
Zafgen Secures $45 Million in Series E Financing

CAMBRIDGE, Mass., Dec. 4, 2013 /PRNewswire/ -- Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced it has secured $45 million in a Series E equity financing.  New investors include RA Capital Management, Brookside Capital, Venrock, Alta Partners, an undisclosed blue chip investor, and a private investor.  Proceeds from the financing will be used to support the continued development of beloranib, the Company's obesity therapeutic.  Zafgen recently reported Phase 2 study results, which demonstrated that beloranib treatment led to significant weight loss and improvements in multiple cardiometabolic risk factors in 147 obese subjects.

"We are excited to add this group of new investors to our syndicate and to obtain continued investment from Alta Partners who led our Series D round last year, as we continue to advance our clinical testing for beloranib in severe obesity and related orphan indications," said Thomas Hughes, Ph.D., president and chief executive officer, Zafgen, Inc.  "With their support, we look forward to building on our recent Phase 2 results and expanding the beloranib program to help patients who suffer from these serious diseases."  

"Zafgen has continued to attract high quality investors to its syndicate in support of beloranib," said Peter Barrett of Atlas Venture and Chairman of the Board of Zafgen.  "Zafgen's newest investors support some of the most innovative companies and their investment demonstrates confidence in beloranib as a unique pharmacotherapeutic with the potential to address the unmet needs of severely obese patients."

About Zafgen, Inc.

Zafgen is an innovative company dedicated to addressing the unmet need of severely obese patients and related orphan indications by bringing beloranib, a first-in-class novel medicine, to market.  Founded in 2005 as a virtual company, Zafgen brings together leading experts in obesity and metabolic disease to address the underserved and growing population of patients who are severely obese.  Zafgen's singular focus is on advancing novel therapeutics for patients suffering from severe obesity and obesity-related disorders.  The company is located in Cambridge, MA.  For more information, visit

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
2. Zafgen Secures $21 Million in Series D Financing
3. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
4. Collaborative Medical Technology Corporation Secures Investments from Two Prominent Medical Specialists
5. Calithera Biosciences Secures $35 Million in Series D Financing
6. Harrisvaccines, Inc. Secures Exclusive Rights From AlphaVax, Inc. to Develop RNA Particle Vaccines for All Diseases in Companion Animals
7. Arvinas Secures $18.25 Million to Advance Clinical Programs Focused on Protein Degradation
8. Predilytics Secures Additional Funding and Expands Board of Directors
9. VisionCare Ophthalmic Technologies Secures Up To $15MM To Accelerate Growth Of Its Novel Treatment For Age-Related Macular Degeneration
10. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
11. Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
Post Your Comments:
(Date:11/29/2015)... and NUREMBERG, Germany , Nov. 29, ... leader Ziehm Imaging invites attendees to experience the most ... market. The highlight on display is Ziehm Vision RFD ... that provides a 16 cm edge length per scan ... Hybrid Edition, the first fully motorized mobile C-arm in ...
(Date:11/27/2015)... --> --> ... The potential to save costs, improve treatment quality and ... fully exploited as yet. Here, particular emphasis is placed ... mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/26/2015)... India , November 27, ... --> --> ... personal emergency response system (PERS) ... steadily for 5 years with ... region expected to see a ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 28, 2015 , ... There is only one major question facing all law ... , This question has not been an easy question to answer. Especially when the ... the younger workforce don’t share the same discipline around working long hours. , ...
(Date:11/27/2015)... ... 27, 2015 , ... A team of Swiss doctors has released a report ... has just posted the findings on the website. Click here to read the ... 136 mesothelioma patients who were treated with chemotherapy followed by EPP surgery. Among the ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... ... use in Final Cut Pro X. With ProSidebar: Fasion, video editors can easily ... use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating drop zones, ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... Consultants has prided itself for not only fulfilling the needs of advisers and ... at an affordable price and providing top-tier customer service. However, there's always room ...
(Date:11/27/2015)... Francisco, California (PRWEB) , ... November 27, 2015 , ... ... Janis Joplin Ann Arbor Michigan boxing style concert posters. This is one of Joplin's ... at the Canterbury House at the University of Michigan in Ann Arbor. The According ...
Breaking Medicine News(10 mins):